|
Undiscounted
| | | |
|
CIN1 cases
|
8 217
|
9 020
|
−803
|
|
CIN2/3 cases
|
1 294
|
1 945
|
−651
|
|
Genital warts cases
|
9 688
|
2 755
|
6 933
|
|
Cervical cancer cases
|
113
|
161
|
−48
|
|
Cervical cancer deaths
|
38
|
54
|
−16
|
|
Life Years
|
7 163 635
|
7 163 268
|
367
|
|
Quality adjusted life years (QALY)
|
7 163 094
|
7 162 817
|
276
|
|
Lifetime cost of strategy
|
$127 212 309
|
$129 344 736
|
-$2 132 427
|
|
Incremental cost per QALY gained
| | |
A Dominates B
|
|
Discounted outcomes
| | | |
|
Life Years
|
2 982 064
|
2 981 994
|
70
|
|
QALY
|
2 981 855
|
2 981 854
|
1
|
|
Lifetime cost of strategy
|
$75 010 163
|
$75 693 270
|
-$683 107
|
|
Incremental cost per QALY gained
| | |
A Dominates B
|
